Table 2.
Study and participant characteristics.
| Study | Country | Study Design |
Group | Sample Size | Follow-Up | Age * | % Male | Etiology | Ejection Fraction * |
|---|---|---|---|---|---|---|---|---|---|
| [13] | Greece | Prospective cohort study | Total | 24 | NR | Ischemic HF | |||
| Treatment | 12 | 50.1 ± 8.5 | 91.66 | 27.2 ± 6.8 | |||||
| Control | 12 | 64.8 ± 10.8 | 91.66 | 33.9 ± 69.1 | |||||
| [14] | Germany | RCT | Total | 204 | 24 months | 56 ± 11 | 82 | Ischemic HF | |
| Treatment | 103 | 57 ± 11 | NR | 45.4 ± 9.4 | |||||
| Control | 101 | 55 ± 11 | NR | 48.7 ± 10.4 | |||||
| [15] | Germany | Retrospective cohort study | Total | 775 | 1 month | ||||
| AMI | 126 | 54 ± 11 | 93.65 | AMI | 49 ± 10 | ||||
| Chronic HF | 562 | 62 ± 11 | 88.26 | Ischemic HF | 37 ± 11 | ||||
| Chronic HF | 87 | 57 ± 14 | 75.86 | Non-ischemic HF | 31 ± 11 | ||||
| [16] | UK | RCT | Total | 9 | 12 months | Ischemic HF | |||
| Treatment | 5 | 59 ± 11 | 80 | 30.5 ± 11.9 | |||||
| Control | 4 | 58 ± 4 | 100 | 27.8 ± 10.1 | |||||
| [17] | UK | RCT | Total | 27 | NR | Ischemic HF | |||
| Intramyocardial BMSC group | 8 | 67.1 ± 10.5 | 100 | 32.0 ± 9.1 | |||||
| Intracoronary serum group | 8 | 59.3 ± 12.2 | 100 | 32.4 ± 8.3 | |||||
| BMSC Group | 5 | 62.0 ± 8.9 | 100 | 30.1 ± 3.4 | |||||
| Serum Group | 6 | 63.8 ± 6.6 | 100 | 27.6 ± 10.9 | |||||
| [18] | China | RCT | Total | 42 | 12 months | Ischemic HF | |||
| CABG | 18 | 56.56 ± 9.09 | 96 | NR | |||||
| CABG + BMMNC | 24 | 57.88 ± 8.52 | 94.4 | NR | |||||
| [19] | Brazil | RCT | Total | 22 | <1190 days | NR | NR | NR | 31.4 ± 10 |
| G-CSF (control) | 14 | NR | NR | NR | 29 ± 6.9 | ||||
| BMSC | 8 | NR | NR | NR | 35.8 ± 11.8 |
* Values reported as mean ± SD. NR = Not reported.